Liquid Biopsies and Biomarker Discovery at CIOC 2027

Liquid biopsy is an emerging, non-invasive method for detecting cancer through the analysis of blood samples, providing an alternative to traditional tissue biopsies. This technique focuses on identifying tumor-derived materials, such as circulating tumor DNA (ctDNA) or RNA, which are shed into the bloodstream by cancer cells. Liquid biopsies offer significant advantages, including earlier detection of cancers, monitoring of disease progression, and tracking treatment responses, all without the need for invasive surgical procedures. One of the key benefits is their ability to detect genetic mutations and tumor heterogeneity, providing real-time insights into how a cancer may evolve or respond to therapy. With continued advancements in technology, liquid biopsy is poised to become a routine tool for cancer diagnostics, allowing for timely interventions and personalized treatment plans that improve patient outcomes while minimizing the risks associated with traditional biopsy methods.